Sino Biopharm
Sino Biopharm is the master of commercial partnerships; it utilizes its unparalleled sales network to distribute innovative drugs for global partners while building its own massive oncology and liver disease portfolio.
Revenue
$4.2B
~$4.2 billion USD
Profitability
Highly Profitable
Division
Healthcare and Biotech
Public
Headquarters
Hong Kong / Beijing
Tse Ping
Operating Model
What They Do
Sino Biopharm is a research driven pharmaceutical conglomerate. They dominate the Chinese markets for liver disease (Hepatitis) and oncology, operating through subsidiaries like Chia Tai Tianqing.
Who They Serve
Chinese domestic patients and global biotech firms seeking a powerful mainland distribution partner.
Moat: Where They Win
Sales Force Supremacy
Operates one of the largest and most professionalized medical sales teams in China.
Precision M&A
Uses its cash pile to acquire stakes in innovative global biotechs, such as its strategic investment in Sinovac during the pandemic.
Liver Disease Moat
Holds a near monopoly on several critical Hepatitis treatments in China.
Business Model
Model Type
Revenue Streams
Profitability
Status
Highly Profitable
Revenue
$4.2B
est.
Division
Healthcare and Biotech
Public
Margin Profile
Maintains high net margins through a lean R&D model that focuses on high probability clinical molecules and aggressive sales execution.
Catalyst: Why Now
Sino Biopharm is aggressively divesting legacy, low growth assets to focus entirely on high margin innovation. In 2025, they announced several blockbuster clinical breakthroughs in oncology that are expected to drive double digit growth through 2030.
Competitive Landscape
* Competitive threat index · China domestic market positioning
Western Analogs
Mental model only, not a 1:1 comparison
Founder
Tse Ping
Founder & CEO
Tse Ping belongs to the billionaire Dhanin Chearavanont family (CP Group). He built Sino Biopharm into a standalone powerhouse by focusing on professional management and the then underserved liver disease market in China.